How many antisense oligonucleotides drugs are tracked?

Drug Landscape tracks 29 antisense oligonucleotides (22 marketed, 0 Phase 3, 0 Phase 2, 7 Phase 1).

How fresh is this page?

Refreshed every 30 minutes from primary sources (Drugs@FDA, EMA EPAR, ClinicalTrials.gov, sponsor 8-K filings).

Antisense Oligonucleotides — Pipeline, Approvals, Sponsors

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antisense oligonucleotide therapeutics — synthetic single-stranded RNA/DNA hybrids that bind mRNA to modify processing or degradation. Spinraza (SMN2 splicing), Tegsedi, Waylivra. Strong neurology + rare disease pipeline.

Marketed

Filed

Phase 3

Phase 2

Phase 1

Total

Marketed leaders

2025-01-01 — Qfitlia · Genzyme Corp · Antithrombin-directed RNA Interaction [EPC] · Rare Disease
2025-01-01 — Dawnzera · Ionis Pharms Inc · Pain
2025-01-01 — Rivfloza · Novo · Metabolic
2025-01-01 — Redemplo · Arrowhead · APOC-III-directed RNA Interaction [EPC] · Metabolic
2025-01-01 — Wainua · Astrazeneca Ab · Transthyretin-directed RNA Interaction [EPC] · Neuroscience
2023-01-01 — Izervay · Astellas Pharma · Immunology
2023-01-01 — Qalsody · Biogen Ma · Antisense Oligonucleotide [EPC] · Rare Disease
2022-01-01 — Amvuttra · Alnylam Pharmaceuticals · Small Interfering RNA · Neuroscience
2021-01-01 — Leqvio · Novartis · Metabolic
2021-01-01 — Amondys 45 · Sarepta · Antisense Oligonucleotide [EPC] · Rare Disease
2020-01-01 — Oxlumo · Alnylam Pharmaceuticals · Metabolic
2020-01-01 — Viltepso · Nippon Shinyaku · Rare Disease

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Drug classes within Antisense Oligonucleotides

Antisense Oligonucleotide [EPC] · 4
Small Interfering RNA · 3
Antisense Oligonucleotide · 1
Antithrombin-directed RNA Interaction [EPC] · 1
Survival Motor Neuron-2-directed RNA Interaction [EPC] · 1
Transthyretin-directed RNA Interaction [EPC] · 1
APOC-III-directed RNA Interaction [EPC] · 1
fomivirsen · 1
Aminolevulinate Synthase 1-directed RNA Interaction · 1

Subscribe to ongoing alerts

Push every new antisense oligonucleotides event into your RSS reader:

Other modalities

Biologics Monoclonal Antibodies Small Molecules Antibody-Drug Conjugates Cell Therapies Gene Therapies Gene Editing mRNA Therapeutics siRNA Therapeutics Bispecific Antibodies Vaccines

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing